

# Selisistat

Catalog No: tcsc0960



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 25mg



## Specifications

**CAS No:**

49843-98-3

**Formula:**

$C_{13}H_{13}ClN_2O$

**Pathway:**

Epigenetics;Cell Cycle/DNA Damage

**Target:**

Sirtuin;Sirtuin

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 32$  mg/mL (128.66 mM)

**Alternative Names:**

EX-527

**Observed Molecular Weight:**

248.71


## Product Description

Selisistat (EX-527) is a potent and selective **SIRT1** inhibitor with **IC<sub>50</sub>** of 98 nM.

IC50 & Target: IC50: 98 nM (SIRT1), 19.6 μM (SIRT2), 48.7 μM (SIRT3)<sup>[4]</sup>

**In Vitro:** Selisistat (EX-527) is an inhibitor of SIRT1 enzymatic activity (IC<sub>50</sub>, 98 nM), identified in a high-throughput screen using bacterially expressed human SIRT1. Selisistat (EX-527) inhibits SIRT1 in a concentration-dependent manner with an IC<sub>50</sub> of 38 nM, in agreement with the activity on bacterially expressed SIRT1. Selisistat (EX-527) has much lower potency against SIRT2 (IC<sub>50</sub>, 19.6 μM) or SIRT3 (IC<sub>50</sub>, 48.7 μM) but does not inhibit class I/II HDAC activity at concentrations up to 100 μM<sup>[1]</sup>. Selisistat (EX-527) exerts an inhibitory effect on SIRT1 activity without affecting SIRT1 expression on both mRNA and protein levels<sup>[2]</sup>.

**In Vivo:** Selisistat (EX-527) abolishes Resveratrol (RSV)-induced attenuation of microvascular inflammation in *ob/ob* septic mice. Finally, *ob/ob* mice in Sepsis+RSV group has significantly increased 7-day survival vs. Sepsis+Vehicle group<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!